Literature DB >> 34182535

Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients With Locally Advanced Breast Cancer and Partial Response After Neoadjuvant Chemotherapy.

Marco Pellicciaro1, Marco Materazzo2, Chiara Buonomo3, Gianluca Vanni1.   

Abstract

BACKGROUND/AIM: Axillary reverse mapping (ARM) aims to identify and preserve arm drainage in order to prevent lymphedema following axillary lymph node dissection. Oncological-safety and feasibility are still debated, especially in patients with locally-advanced breast cancer (LABC). We report the first case of the AXMAP 1.0 study performed in our Institution. PATIENTS AND METHODS: A 52-year-old patient with a triple-negative LABC and partial response to neoadjuvant chemotherapy underwent axillary lymph-node dissection using fluorescence ARM.
RESULTS: Two lymph-nodes draining the ipsilateral upper arm were identified and were not preserved due to suspicion of malignancy. Pathological examination confirmed the presence of malignancy in both lymph nodes.
CONCLUSION: Further studies should be designed in order to validate the oncological safety of this technique, especially in patients with LABC requiring neoadjuvant chemotherapy.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast neoplasm; axillary imaging; axillary lymph node dissection; axillary reverse mapping; local advanced breast cancer

Year:  2021        PMID: 34182535     DOI: 10.21873/invivo.12529

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Lu Li; Yue Yang; Wang Li; Xian Zhao; Jia He; Shuo Mei; Xuejun Guo; Xibin Zhang; Jianghua Ran
Journal:  World J Surg Oncol       Date:  2022-04-27       Impact factor: 3.253

2.  Dexmetomidine promotes the activity of breast cancer cells through miR-199a/HIF-1α axis.

Authors:  Gang Wen; Naixing Xin
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.